公开(公告)号：US20180355362A1

公开(公告)日：2018-12-13

申请号：US16105522

申请日：2018-08-20

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US10081811B2

公开(公告)日：2018-09-25

申请号：US15661132

申请日：2017-07-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US20160272979A1

公开(公告)日：2016-09-22

申请号：US15166576

申请日：2016-05-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C12N15/113

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

摘要翻译： 本公开内容涉及可用于使用治疗有效量的β-半乳糖苷酶治疗β-肾上腺素相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压） RNAi试剂至β-ENaC。

公开(公告)号：US10550391B2

公开(公告)日：2020-02-04

申请号：US16105522

申请日：2018-08-20

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/713

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US20170327829A1

公开(公告)日：2017-11-16

申请号：US15661132

申请日：2017-07-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.

公开(公告)号：US09752152B2

公开(公告)日：2017-09-05

申请号：US15166576

申请日：2016-05-27

申请人： Arrowhead Pharmaceuticals, Inc.

发明人： Antonin De Fougerolles ,  John Diener ,  Emma Hickman ,  Gregory Hinkle ,  Stuart Milstein ,  Anne-Marie Pulichino ,  Andrew Griffin Sprague

IPC分类号： C07H21/02 ,  C07H21/04 ,  A61K48/00 ,  C12N15/113 ,  A61K31/713

CPC分类号： C12N15/1138 ,  A61K31/713 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/31 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/351 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/3517 ,  C12N2310/3521

摘要： The present disclosure relates to RNAi agents useful in methods of treating BetaENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.